{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:49:02Z","timestamp":1758815342308},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.urology.2008.10.056","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T09:37:40Z","timestamp":1232789860000},"page":"922-927","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Antiepileptic Agent, Levetiracetam, on Urodynamic Parameters and Neurogenic Bladder Overactivity in Chronically Paraplegic Rats"],"prefix":"10.1016","volume":"73","author":[{"given":"Ehab A.","family":"Elzayat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lysanne","family":"Campeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Karsenty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Blok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ante L.","family":"Padjen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Corcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2008.10.056_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0090-4295(02)01803-4","article-title":"Muscarinic receptor subtypes and management of the overactive bladder","volume":"60","author":"Chapple","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.10.056_bib2","first-page":"S7","article-title":"Pathophysiology of overactive bladder and urge urinary incontinence","volume":"4","author":"Steers","year":"2002","journal-title":"Rev Urol"},{"key":"10.1016\/j.urology.2008.10.056_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1469-445X.1999.tb00083.x","article-title":"Advances in the pharmacological control of the bladder","volume":"84","author":"Andersson","year":"1999","journal-title":"Exp Physiol"},{"issue":"suppl 1","key":"10.1016\/j.urology.2008.10.056_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2003.10.005","article-title":"New pharmacologic targets for the treatment of the overactive bladder: an update","volume":"63","author":"Andersson","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.10.056_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/01.WNF.0000228174.08885.AB","article-title":"Gabapentin treatment of neurogenic overactive bladder","volume":"29","author":"Carbone","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.urology.2008.10.056_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1590\/S1677-55382004000400002","article-title":"Gabapentin for overactive bladder and nocturia after anticholinergic failure","volume":"30","author":"Kim","year":"2004","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urology.2008.10.056_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pharmthera.2006.07.005","article-title":"Novel anticonvulsant drugs","volume":"113","author":"Stefan","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.urology.2008.10.056_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(03)01933-2","article-title":"Antihyperanalgesic effect of levetiracetam in neuropathic pain models in rats","volume":"473","author":"Ardid","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.urology.2008.10.056_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00002508-200401000-00007","article-title":"Levetiracetam in the treatment of neuropathic pain: three case studies","volume":"20","author":"Price","year":"2004","journal-title":"Clin J Pain"},{"key":"10.1016\/j.urology.2008.10.056_bib10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.urology.2008.10.056_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001756-199702100-00002","article-title":"Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation","volume":"8","author":"Stanfa","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.urology.2008.10.056_bib12","first-page":"47","article-title":"Oral gabapentin (Neurontin) treatment of refractory genitourinary tract pain","volume":"7","author":"Sasaki","year":"2001","journal-title":"Tech Urol"},{"key":"10.1016\/j.urology.2008.10.056_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.neuropharm.2003.11.010","article-title":"Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P\/Q-type Ca2+ channels","volume":"46","author":"Bayer","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.urology.2008.10.056_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.urology.2008.10.056_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0028-3908(03)00248-X","article-title":"Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?","volume":"45","author":"Madeja","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.urology.2008.10.056_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0028-3908(01)00185-X","article-title":"Levetiracetam opposes the action of GABA antagonists in hypothalamic neurons","volume":"42","author":"Poulain","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.urology.2008.10.056_bib17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950801830X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950801830X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T07:51:02Z","timestamp":1545465062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042950801830X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S009042950801830X"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2008.10.056","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}